Altimmune has launched its PERFORMA Phase 3 trial in MASH, advancing its lead liver-disease program into late-stage testing. The move underscores its push to ad

Altimmune has launched its PERFORMA Phase 3 trial in MASH, advancing its lead liver-disease program into late-stage testing. The move underscores its push to address unmet patient need in serious liver conditions and expand its hepatology pipeline.